Trials / Completed
CompletedNCT00781170
Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma
Dose-Reduced Allogeneic Stem Cell Transplantation as Induction of a Graft-Versus-Myeloma-Effect After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma Stage II/III
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf · Academic / Other
- Sex
- All
- Age
- 18 Years – 66 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the feasibility and efficacy of a autologous stem cell transplantation followed by a Melphalan/ Fludarabine based dose-reduced allograft from HLA-identical and HLA-compatible unrelated donor in patients with Multiple Myeloma. In those with non complete remission DLI and/ or new agents such as Bortezomib, Thalidomid or Lenalidomide can be used to upgrade remission.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | allogeneic hematopoietic SCT |
Timeline
- Start date
- 2000-05-01
- First posted
- 2008-10-28
- Last updated
- 2009-05-28
Source: ClinicalTrials.gov record NCT00781170. Inclusion in this directory is not an endorsement.